JUNS Stock Overview

A clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. More details

JUNS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 51.54% per year

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

Shares are highly illiquid

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Jupiter Neurosciences, Inc. Competitors

Atea Pharmaceuticals

NasdaqGS:AVIR

US$276.2m

Atai Life Sciences

NasdaqGM:ATAI

US$251.7m

Terns Pharmaceuticals

NasdaqGS:TERN

US$425.5m

ALT5 Sigma

NasdaqCM:ALTS

US$88.9m

Price History & Performance

Summary of share price highs, lows and changes for Jupiter Neurosciences
Historical stock prices
Current Share Price	US$8.55
52 Week High	US$19.51
52 Week Low	US$3.86
Beta	0
1 Month Change	-29.98%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	55.74%

Recent updates

Shareholder Returns

	JUNS	US Pharmaceuticals	US Market
7D	0.6%	0.5%	-2.1%
1Y	n/a	2.3%	21.3%

Return vs Industry: Insufficient data to determine how JUNS performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how JUNS performed against the US Market.

Price Volatility

Is JUNS's price volatile compared to industry and market?
JUNS volatility
JUNS Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	11.1%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.9%
10% least volatile stocks in US Market	3.2%

Stable Share Price: JUNS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine JUNS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2015	4	Christer Rosen	jupiterneurosciences.com

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. The company is also developing JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome.

Jupiter Neurosciences, Inc. Fundamentals Summary

How do Jupiter Neurosciences's earnings and revenue compare to its market cap?
JUNS fundamental statistics
Market cap	US$283.04m
Earnings (TTM)	-US$1.34m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-211.0x

P/E Ratio

Is JUNS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JUNS income statement (TTM)
Revenue	US$0
Cost of Revenue	US$536.39k
Gross Profit	-US$536.38k
Other Expenses	US$805.26k
Earnings	-US$1.34m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.041
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-39.7%

How did JUNS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/12 14:47
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jupiter Neurosciences, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
William Gregozeski	Greenridge Global LLC

Jupiter Neurosciences NasdaqCM:JUNS Stock Report